We sort of have another merger Monday but again not what SMID investors were hoping for and another one that might have limited read through to the broader sector. That.
The market seems odd to me. Earnings so far have been good and the individual stocks are going higher on the earnings and holding onto the gains. The rest of.
This is an odd day in the market. You get the first important large cap earnings, which usually drives the rest of the sector but there is no connection. BIIB.
I am back and need to catch up on the overall market and some sector news. I do want to focus today on a stock we all know and will.
I am back from vacation and have a couple of days to get as much work done before I am taking care of some family issues. I should have some.
Pfizer (PFE) presented its first set of data (n=6) from the mini-dystrophin gene therapy for DMD (PF-06939926) at the PPMD conference on June 28th. Much speculations surrounded Pfizer’s decision to.
A good finish to the week so far in the sector. I will try and keep this quick and to the point as it is a little delayed because of.
So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its.
The sector continues to do well but we may have some additional macro coming with the Iran downing of an American drone in international waters. The market does not seem.
It is a good start to the week with merger Monday coming back the sector albeit with names we were not expecting. The XBI has been in a nice tight.
I am back but honestly we are entering the summer quite period with little news to drive the sector higher or lower. We did get a break from the macro,.